A district court judge vanquished Janssen Biotech Inc.'s hopes of delaying the launch of Celltrion Inc./Pfizer Inc.'s Remicade (infliximab) biosimilar until the composition patent expires in September 2018.
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?